- Home
- VCIC vs DMAC Comparison
VCIC vs DMAC Comparison
Compare VCIC & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCIC
- DMAC
- Stock Information
- Founded
- VCIC 2024
- DMAC 2000
- Country
- VCIC United States
- DMAC United States
- Employees
- VCIC N/A
- DMAC N/A
- Industry
- VCIC
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- VCIC
- DMAC Health Care
- Exchange
- VCIC NYSE
- DMAC Nasdaq
- Market Cap
- VCIC 304.0M
- DMAC 178.0M
- IPO Year
- VCIC 2024
- DMAC N/A
- Fundamental
- Price
- VCIC $10.40
- DMAC $3.63
- Analyst Decision
- VCIC
- DMAC Strong Buy
- Analyst Count
- VCIC 0
- DMAC 2
- Target Price
- VCIC N/A
- DMAC $8.00
- AVG Volume (30 Days)
- VCIC 4.1K
- DMAC 325.9K
- Earning Date
- VCIC 01-01-0001
- DMAC 08-06-2025
- Dividend Yield
- VCIC N/A
- DMAC N/A
- EPS Growth
- VCIC N/A
- DMAC N/A
- EPS
- VCIC N/A
- DMAC N/A
- Revenue
- VCIC N/A
- DMAC N/A
- Revenue This Year
- VCIC N/A
- DMAC N/A
- Revenue Next Year
- VCIC N/A
- DMAC N/A
- P/E Ratio
- VCIC $77.98
- DMAC N/A
- Revenue Growth
- VCIC N/A
- DMAC N/A
- 52 Week Low
- VCIC $9.96
- DMAC $2.98
- 52 Week High
- VCIC $10.74
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- VCIC N/A
- DMAC 44.55
- Support Level
- VCIC N/A
- DMAC $3.48
- Resistance Level
- VCIC N/A
- DMAC $3.88
- Average True Range (ATR)
- VCIC 0.00
- DMAC 0.26
- MACD
- VCIC 0.00
- DMAC 0.00
- Stochastic Oscillator
- VCIC 0.00
- DMAC 30.10
About VCIC VINE HILL CAP INVT CORP
Vine Hill Capital Investment Corp is a blank check company.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.